Compare · DFTX vs ONCR
DFTX vs ONCR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.71B, about 57.2x ONCR ($82.3M).
- DFTX has hit the wire 7 times in the past 4 weeks while ONCR has been quiet.
- DFTX has more recent analyst coverage (5 ratings vs 0 for ONCR).
- Company
- Definium Therapeutics Inc.
- Oncorus Inc.
- Price
- $43.14+0.54%
- $0.12-10.15%
- Market cap
- $4.71B
- $82.3M
- 1M return
- +2.42%
- -
- 1Y return
- +341.56%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 0
- Recent ratings
- 5
- 0
Oncorus Inc.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest ONCR
- SEC Form DEFA14A filed by Oncorus Inc.
- SEC Form 15-12G filed by Oncorus Inc.
- SEC Form DEFA14A filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Leadership Update, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form RW filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update